105 related articles for article (PubMed ID: 466976)
21. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
[TBL] [Abstract][Full Text] [Related]
22. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
[TBL] [Abstract][Full Text] [Related]
23. Changes in the coagulation and fibrinolytic systems predisposing to thrombosis.
Nilsson IM
Acta Chir Scand Suppl; 1968; 387():15-22. PubMed ID: 4240349
[No Abstract] [Full Text] [Related]
24. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
Jespersen J
Dan Med Bull; 1988 Feb; 35(1):1-33. PubMed ID: 3277796
[TBL] [Abstract][Full Text] [Related]
25. [Therapeutic effect of pyridylcarbinolic ester of clofibric acid on the changes of the lipid and fibrinolytic picture in arteriosclerotic patients].
Rugginenti
Minerva Med; 1974 May; 65(35):1906-16. PubMed ID: 4601840
[No Abstract] [Full Text] [Related]
26. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
[TBL] [Abstract][Full Text] [Related]
27. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
28. -Pyridylcarbinol in experimental hypercholesterinemia of the rabbit. Study of lipidic fractions and of the mechanisms of hemostasis.
Giarola P; Egge H; Gibelli A; Müller J
Farmaco Sci; 1972 Nov; 27(11):1018-23. PubMed ID: 4647185
[No Abstract] [Full Text] [Related]
29. Metabolic effects of clofibrate on experimental animals.
Bedö M; Kramer M; Blaskovits A; Gefferth G; Tarjan R
Arzneimittelforschung; 1978; 28(7):1076-80. PubMed ID: 582692
[TBL] [Abstract][Full Text] [Related]
30. [Undesirable drug effects on the blood clotting and fibrinolysis].
Kanabus P
Pol Tyg Lek; 1978 Oct; 33(40):1577-80. PubMed ID: 704463
[No Abstract] [Full Text] [Related]
31. [Effects of hydroxyethyl starch on blood coagulation and fibrinolysis. II. In vivo studies].
Matsuda T; Murakami S; Hashizume K
Rinsho Ketsueki; 1972 Dec; 13(6):934-8. PubMed ID: 4675064
[No Abstract] [Full Text] [Related]
32. [Fibrinolytic action of aluminum bis-alpha-para-chlorophenoxy isobutyrate].
Daver J; Ripoll S; Du Pasquier JP; Edmond E; Palus JC; Ricoeur M; Aubert D
Therapie; 1969; 24(3):419-28. PubMed ID: 5399537
[No Abstract] [Full Text] [Related]
33. Effects of etofibrate, clofibrate and nicotinic acid on lipid metabolism in normolipemic rats.
Priego JG; Maroto ML; Piña M; Catalan RE
Gen Pharmacol; 1979; 10(3):215-9. PubMed ID: 467961
[No Abstract] [Full Text] [Related]
34. Comparative clinical study of the effects of Na isobutyrate and clofibrate on the clotting factors in patients with atherosclerosis.
Papilian-Stoichiţă M; Chiosa L; Niţă I
Med Interne; 1979; 17(2):169-74. PubMed ID: 472639
[TBL] [Abstract][Full Text] [Related]
35. Comparative studies on the influence of Provasan, Complamine, Sadamine, A-100 and Clofibrat on the behaviour of some lipid fractions of plasma in experimental animals.
Sulowska Z
Mater Med Pol; 1974; 6(2):102-6. PubMed ID: 4431240
[No Abstract] [Full Text] [Related]
36. [Considerations on the changes of the coagulation and fibrinolytic picture and of uricemia during therapy with heparin in low doses. Relations with the change of the lipemic level].
Lombardi V; Bonini M
Minerva Med; 1970 Oct; 61(87):4889-92. PubMed ID: 5488539
[No Abstract] [Full Text] [Related]
37. Hypolipaemic activity of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate) and its analogues in normolipaemic rats.
Ginocchio AV; Metz G
Arzneimittelforschung; 1980; 30(11b):2032-4. PubMed ID: 7194054
[TBL] [Abstract][Full Text] [Related]
38. Prolonged plasma clotting time and decreased fibrinolysis after long term treatment with alpha-tocopherol.
Korsan-Bengtsen K; Elmfeldt D; Holm T
Thromb Diath Haemorrh; 1974 Jun; 31(3):505-12. PubMed ID: 4422949
[No Abstract] [Full Text] [Related]
39. [Our experience using nicotinic acid for preventing thromboembolic complications].
Chekalina SI; Tokarev OIu
Sov Med; 1982; (5):105-8. PubMed ID: 7112226
[No Abstract] [Full Text] [Related]
40. Blood clotting, plasma kinins and fibrinolysis.
Gjonnaess H; Stormorken H
Thromb Diath Haemorrh; 1970 Oct; 24(1):308-10. PubMed ID: 5483971
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
